Drugs / KBP-7072
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05507463 | Aug 2022 → Jun 2023 | — | KBP Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT04532957 | Aug → Oct 2020 | — | KBP Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT02654626 | Oct → Dec 2015 | — | KBP Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT02454361 | May → Oct 2015 | — | KBP Biosciences | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KBP-7072 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04532957 ↗ |
| Modality | Small molecule | “KBP-7072 is a novel third-generation tetracycline (aminomethylcycline) antibacterial” PMID 32071042 ↗ Apr 2020 |
| Route | Oral | “Following oral administration” NCT02454361 ↗ |